000			01853 a2200517 4500
005			20250516144245.0
264		0	_c20130816
008			201308s 0 0 eng d
022			_a1097-0142
024	7		_a10.1002/cncr.28051 _2doi
040			_aNLM _beng _cNLM
100	1		_aCrozier, Jennifer A
245	0	0	_aEffect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. _h[electronic resource]
260			_bCancer _cJul 2013
300			_a2447-54 p. _bdigital
500			_aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650	0	4	_aAdenocarcinoma _xchemistry
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntibodies, Monoclonal, Humanized _xtherapeutic use
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aBiomarkers, Tumor _xanalysis
650	0	4	_aBody Mass Index
650	0	4	_aBreast Neoplasms _xchemistry
650	0	4	_aChemotherapy, Adjuvant
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aImmunohistochemistry
650	0	4	_aIn Situ Hybridization, Fluorescence
650	0	4	_aLymphatic Metastasis
650	0	4	_aMiddle Aged
650	0	4	_aReceptor, ErbB-2 _xanalysis
650	0	4	_aReceptors, Estrogen _xanalysis
650	0	4	_aReceptors, Progesterone _xanalysis
650	0	4	_aTrastuzumab
650	0	4	_aTreatment Outcome
700	1		_aMoreno-Aspitia, Alvaro
700	1		_aBallman, Karla V
700	1		_aDueck, Amylou C
700	1		_aPockaj, Barbara A
700	1		_aPerez, Edith A
773	0		_tCancer _gvol. 119 _gno. 13 _gp. 2447-54
856	4	0	_uhttps://doi.org/10.1002/cncr.28051 _zAvailable from publisher's website
999			_c22668558 _d22668558